Navigation Links
Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
Date:10/11/2011

CAMBRIDGE, Mass., Oct. 11, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a randomized Phase 2 clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, combined with paclitaxel (Taxol®) in the neoadjuvant setting of HER2-negative breast cancer patients.

(Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO)

The Phase 2 study is designed to evaluate whether the combination of MM-121 with paclitaxel is more effective than treatment with paclitaxel alone when administered as part of a neoadjuvant treatment regimen in HER2-negative, locally advanced breast cancer patients. A total of 200 patients are expected to be enrolled in the study. Following treatment with MM-121 and paclitaxel, or paclitaxel alone, patients will receive standard treatment with doxorubicin and cyclophosphamide and monitored until surgical resection. Multiple sites in North America are currently expected to participate in this study. The first patient was enrolled at Texas Oncology - Memorial City.

Merrimack entered into an exclusive, global collaboration and licensing agreement with Sanofi for MM-121 in 2009.

About Merrimack

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has four targeted therapeutic oncology candidates in clinical development and a fifth expected to enter clinical development by early 2012.

Contact: Kathleen Petrozzelli Gallagher, Corporate Communications, Merrimack, 617-441-1043,
kgallagher@merrimackpharma.com
Betsy Stevenson, RaymondStevenson Healthcare Communications, 860-984-1424,
betsy@raymondstevenson.com


'/>"/>
SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer
2. Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
3. Merrimack Pharmaceuticals Announces the Addition of Michael Porter to its Board of Directors
4. Merrimack Pharmaceuticals to Present at the 2010 Stifel Nicolaus Healthcare Conference
5. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
6. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
7. Inspiration Biopharmaceuticals Names John P. Butler Chief Executive Officer
8. Inovio Pharmaceuticals and VGX International to Advance Therapeutic Hepatitis C and Hepatitis B Synthetic Vaccines into Clinical Studies
9. Inovio Pharmaceuticals Leadership for Life Sciences Recognized in the Philadelphia Region
10. Inovio Pharmaceuticals Synthetic Vaccine for Cancer Recognized as Most Promising Research at Global Vaccine Congress
11. OncoMed Pharmaceuticals Names Dr. Jakob Dupont VP Clinical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential ... or the "Company") (NASDAQ: ANTH ). Such investors ... by visiting the firm,s site: www.bgandg.com/anth .   ... and/or directors have violated Sections 10(b) and 20(a) of the ... ...
(Date:1/17/2017)... WASHINGTON , Jan. 17, 2017  In a ... CEO Jo Ann Jenkins outlines AARP,s priorities ... and Social Security, ensuring access to affordable health care ... In the letter Jenkins writes to President-elect Trump ... older Americans are counting on you to protect their ...
(Date:1/17/2017)... 2017 Immune Pharmaceuticals (NASDAQ: IMNP ... that it will hold a Satellite Symposium on February 20th, ... XVI in Munich, Germany . ... of Immunotherapy for the maintenance of remission in AML ... th , 2017 from 12:45 – 13:45 CET in ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... Metro Development Group has broken ... speed technology into the fabric of an entire community. A highlight of this ... wellness in a yet-to-be-named, health focused campus. Leading this initiative in partnership with ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... – will lecture to primary eye care practitioners on the latest breakthroughs in ... upcoming 13th Semi-Annual Continuing Education Symposium, according to eye surgeon, Jeffrey Martin, MD, ...
(Date:1/17/2017)... ... January 17, 2017 , ... SC&H Group, a leading ... a Principal in its IT Advisory Services practice . Rossi is the third ... market demand for strategic IT guidance grows, and the practice continues to expand.     , ...
(Date:1/17/2017)... ... 17, 2017 , ... Lynx Technology Partners (Lynx), ... security companies for consecutive years, today announced the appointment of four members to ... nomination process to a close and positions Lynx for even faster growth in ...
(Date:1/16/2017)... ... 17, 2017 , ... Recently, patients and staff from A Forever Recovery, a ... organizations in support of the annual Binder Park Zoo Halloween celebration known as the ... costumes of all designs coming out to enjoy games, face painting, and lots and ...
Breaking Medicine News(10 mins):